Archived Content

The content on this page is provided for reference purposes only. This content has not been altered or updated since it was archived.

Vaccines, Blood & Biologics

June 27, 2011 Approval Letter (103914/5449) - Fluzone

Our STN:   BL 103914/5449

Sanofi Pasteur Inc.
Attention: Joseph H. Quinn
Discovery Drive
Swiftwater, PA 19370
Dear Mr. Quinn:
We have approved your request to supplement your biologics license application for Influenza Virus Vaccine, Fluzone®, to include the 2011-2012 United States formulation.
Please submit all final printed labeling at the time of use and include implementation information on FDA form 356h. Please provide content of labeling in Structured Product Labeling format. Please provide carton and container labeling in Structured Product Labeling format.
We will include the information contained in the above referenced supplement in your Biologics License Application file.
Sincerely yours,
Jerry P. Weir, Ph.D.
Division of Viral Products
Office of Vaccines
 Research and Review
Center for Biologics
 Evaluation and Research

Page Last Updated: 06/29/2011
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English